Table 5 Clinical chemistry in the PLF at week 104 of the experimental period
Test article | Total dose | Male | Female | ||||||
|---|---|---|---|---|---|---|---|---|---|
(mg/kg) | LDH | μ-TP | μ-ALB | LDH | μ-TP | μ-ALB | |||
(U/L) | (mg/dL) | (µg/mL) | (U/L) | (mg/dL) | (µg/mL) | ||||
Nontreatment | – | (5) | 9 ± 2 | 38.8 ± 8.9 | 81.3 ± 20.3 | (5) | 6 ± 4 | 48.5 ± 16.7 | 115.4 ± 35.7 |
Control | 0 | (5) | 19 ± 20 | 66.5 ± 41.4 | 131.2 ± 62.4 | (5) | 5 ± 2 | 43.3 ± 7.2 | 103.7 ± 16.8 |
MWNT-7 | 0.128 | (5) | 11 ± 2 | 62.0 ± 29.0 | 117.4 ± 42.0 | (5) | 5 ± 1 | 46.8 ± 16.7 | 112.9 ± 38.8 |
MWNT-7 | 0.64 | (5) | 23 ± 17 | 59.6 ± 21.7 | 103.0 ± 18.1 | (5) | 8 ± 4 | 49.2 ± 29.6 | 106.2 ± 62.5 |
MWNT-7 | 3.2 | (1) | 46 | 257.1 | 307.3 | (5) | 32 ± 40 | 136.4 ± 129.8 | 192.0 ± 114.9 |
VGCF™-H | 0.128 | (5) | 8 ± 2 | 40.4 ± 14.3 | 92.9 ± 27.6 | (5) | 6 ± 2 | 44.4 ± 21.7 | 105.0 ± 47.3 |
VGCF™-H | 0.64 | (5) | 13 ± 9 | 58.1 ± 19.4 | 116.8 ± 26.4 | (5) | 11 ± 15 | 51.5 ± 20.7 | 118.8 ± 33.1 |
VGCF™-H | 3.2 | (5) | 13 ± 6 | 81.8 ± 64.0 | 145.9 ± 63.3 | (5) | 10 ± 6 | 61.7 ± 25.5 | 142.3 ± 54.1 |